Palmitoylethanolamide in CNS health and disease.

  title={Palmitoylethanolamide in CNS health and disease.},
  author={Giuseppina Mattace Raso and Roberto Russo and Antonio Calignano and Rosaria Meli},
  journal={Pharmacological research},

Figures from this paper

Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
The potential neuroprotective effects of PEA have been demonstrated in several experimental models of Alzheimer’s disease and a single-photon emission computed tomography case study reported that a mild cognitive impairment patient, treated for 9 months with ultramicronized-PEA/luteolin, presented an improvement of cognitive performances.
Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans
The present review is aimed at illustrating in vitro and in vivo research, as well as human studies, using PEA treatment, alone or in combination with other compounds, in the presence of neurodegeneration.
Roles of N-Acylethanolamines in Brain Functions and Neuropsychiatric Diseases
NAEs are bioactive lipids, structural analogues to the endocannabinoid arachidonoylethanolamide (anandamide), whose functions and properties are being elucidated in recent years and evidence suggests that they might be therapeutically exploited as neuroprotective agents, “anti-addictive” medications, anticonvulsant, and antidepressant.
Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy
It is demonstrated that subchronic administration of PEA significantly alleviates seizure intensity, promotes neuroprotection and induces modulation of the plasma and hippocampal eCB and eiC levels in systemic KA-injected mice.
Classical and Unexpected Effects of Ultra-Micronized PEA in Neuromuscular Function
All the literature reviewed here strongly supports the ability of this endocannabinoid-like molecule to modulate the acetylcholine receptors thus resulting as a valid support for the treatment of human neuromuscular diseases.
Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects
Palmitoylethanolamide (PEA) is an endogenous lipid produced on demand by neurons and glial cells that displays neuroprotective properties. It is well known that inflammation and neuronal damage are
Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy
Palmitoylethanolamide (PEA) is discussed as a putative anti-inflammatory and retinoprotectant compound in the treatment of retinopathies, especially related to glaucoma and diabetes.
Role of N-Acylethanolamines in the Neuroinflammation: Ultramicronized Palmitoylethanolamide in the Relief of Chronic Pain and Neurodegenerative DiseasesRole of N-Acylethanolamines in the Neuroinflammation: Ultramicronized Palmitoylethanolamide in the Relief of Chronic Pain and Neurodegenerative Dise
The effects of m- and um-PEA on Chronic pain and neuroinflammation in several animal models of chronic pain and neudegenerative disorders and in clinical studies are dealt with.


Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease
Chronic treatment with palmitoylethanolamide (PEA) protects against MPTP-induced neurotoxicity and the ensuing functional deficits even when administered once the insult has been initiated, and chronic PEA reversedMPTP-associated motor deficits.
Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease.
The data indicate that PEA is able to blunt Aβ-induced astrocyte activation and to exert a marked protective effect on neurons, and suggest that this compound may provide an effective strategy for AD.
Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice Involvement of allopregnanolone biosynthesis
PPARs in the brain.
Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α
PEA treatment results in decreased numbers of infiltrating astrocytes during Aβ challenge, resulting in significant neuroprotection, and could represent a promising pharmacological tool because it is able to reduce Aβ-evoked neuroinflammation and attenuate its neurodegenerative consequences.
Palmitoylethanolamide Stimulation Induces Allopregnanolone Synthesis in C6 Cells and Primary Astrocytes: Involvement of Peroxisome‐Proliferator Activated Receptor‐α
Evidence is provided indicating the involvement of the saturated acylethanolamide PEA in ALLO synthesis through PPAR‐α in astrocytes and the antioxidative activity of this molecule is explored, confirming its homeostatic and protective role both under physiological and pathological conditions.
Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide
Results indicate that PEA exhibits anti‐inflammatory properties able to counteract Aβ‐induced astrogliosis, and suggest novel treatment for neuroinflammatory/ neurodegenerative processes.
The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.
  • S. Skaper, A. Buriani, A. Leon
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 1996
The results suggest that non-CB1 cannabinoid receptors control, upon agonist binding, the downstream consequences of an excitotoxic stimulus and activation of such receptors may serve to downmodulate deleterious cellular processes following pathological events or noxious stimuli in both the nervous and immune systems.